GlobalData on MSN

CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension

CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
BioWorld

Items Tagged with 'beta2-adrenergic receptor agonist'

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in ...
Medical News Today

Chronic pain: Non-opioid drug candidates could offer relief without addiction

Share on Pinterest A recent study used computational methods to identify novel compounds that activate receptors involved in pain modulation without sedation. Peter Dazeley/Getty Images Research on ...
Pharmabiz

US FDA approves Viatris & Ocuphire Pharma’s Ryzumvl 0.75% eye drops to treat pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents

Viatris Inc., a global healthcare company, and Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved ...